Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/140760
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCaminero, José A .-
dc.contributor.authorGarcía-Basteiro, Alberto L.-
dc.contributor.authorRendon, Adrian-
dc.date.accessioned2019-09-23T13:57:24Z-
dc.date.available2019-09-23T13:57:24Z-
dc.date.issued2019-07-27-
dc.identifier.issn0140-6736-
dc.identifier.urihttp://hdl.handle.net/2445/140760-
dc.description.abstractThe ideal number of drugs needed and treatment duration are crucial issues in the management of multidrug-resistant tuberculosis (MDR-TB). Thus, we read with interest the Article by the Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment–2017,1 the results of which support our proposal,2 from 2015, to classify anti-tuberculosis drugs on the basis of their toxicity, and sterilising or bactericidal activity.-
dc.format.extent1 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier-
dc.relation.isformatofVersió postprint del document publicat a: http://dx.doi.org/10.1016/S0140-6736(19)30696-8-
dc.relation.ispartofThe Lancet, 2019, vol. 394, num. 10195, p. 298-
dc.relation.urihttp://dx.doi.org/10.1016/S0140-6736(19)30696-8-
dc.rights(c) Elsevier, 2019-
dc.sourceArticles publicats en revistes (ISGlobal)-
dc.subject.classificationTuberculosi-
dc.subject.classificationResistència als medicaments-
dc.subject.otherTuberculosis-
dc.subject.otherDrug resistance-
dc.titleMultidrug-resistant tuberculosis-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.date.updated2019-08-09T18:00:35Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid23190229-
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
CamineroJA_Lancet_2019_Correspondence.pdf66.23 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.